Kezar Life Sciences Inc reports results for the quarter ended in December - Earnings Summary

Kezar Life Sciences

14/03/2024 20:27

* Kezar Life Sciences Inc  KZR.OQ  reported a quarterly
adjusted
loss of 44 cents​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of -25 cents.  The mean expectation of six analysts for the
quarter was for a loss of 38 cents per share. Wall Street
expected results to range from -43 cents to -34 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kezar Life Sciences Inc's reported EPS for the quarter was
a
loss of 44 cents​.
    * The company reported a quarterly loss of $32.26 million.
    * Kezar Life Sciences Inc shares had fallen by 3.9% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Kezar Life
Sciences Inc is $13.00 
This summary was machine generated from LSEG data March 14 at
08:26 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.38          -0.44          Missed
 Sep. 30 2023      -0.35          -0.32          Beat
 Jun. 30 2023      -0.32          -0.34          Missed
 Mar. 31 2023      -0.29          -0.31          Missed